NCT00788775 2018-11-15
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Dana-Farber Cancer Institute
Phase 2 Completed
Dana-Farber Cancer Institute
Institute of Cancer Research, United Kingdom
Novartis
Assistance Publique - Hôpitaux de Paris